P0636 Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance studyFernando Magro, Séverine Vermeire, M Dubinsky et al.|Journal of Crohn s and Colitis|2025Cited by 1
P0813 Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitisSéverine Vermeire, B E Sands, Laurent Peyrin‐Biroulet et al.|Journal of Crohn s and Colitis|2025Cited by 0
DOP048 Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QDSilvio Danese, Séverine Vermeire, B E Sands et al.|Journal of Crohn s and Colitis|2025Cited by 0